Abs-1230
KCNT1-Related Epilepsy
Actio Biosciences, Inc.Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the KCNT1-Related Epilepsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Omeprazole Actio Biosciences, Inc. | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →